CZ2002782A3 - Radiofarmaceutické produkty a způsob jejich přípravy - Google Patents

Radiofarmaceutické produkty a způsob jejich přípravy Download PDF

Info

Publication number: CZ2002782A3
Authority: CZ; Czechia
Prior art keywords: polysaccharide; groups; group; sequestering; starch
Prior art date: 1999-09-01

Application number

CZ2002782A

Other languages

Czech (cs)

English (en)

Inventor

Emmanuel Bellande

Pierre Jallet

Benoît Denizot

Original Assignee

Schering Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-01

Filing date

2000-08-23

Publication date

2002-08-14

2000-08-23 Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft

2002-08-14 Publication of CZ2002782A3 publication Critical patent/CZ2002782A3/cs

Links

239000012217 radiopharmaceutical Substances 0.000 title claims abstract description 29
229940121896 radiopharmaceutical Drugs 0.000 title abstract description 9
230000002799 radiopharmaceutical effect Effects 0.000 title abstract description 9
238000004519 manufacturing process Methods 0.000 title description 2
150000004676 glycans Chemical class 0.000 claims abstract description 46
229920001282 polysaccharide Polymers 0.000 claims abstract description 46
239000005017 polysaccharide Substances 0.000 claims abstract description 46
238000000034 method Methods 0.000 claims abstract description 44
229910052713 technetium Inorganic materials 0.000 claims abstract description 40
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims abstract description 40
230000014759 maintenance of location Effects 0.000 claims abstract description 26
230000002685 pulmonary effect Effects 0.000 claims abstract description 24
229910052751 metal Inorganic materials 0.000 claims abstract description 18
239000002184 metal Substances 0.000 claims abstract description 18
230000002285 radioactive effect Effects 0.000 claims abstract description 17
125000003118 aryl group Chemical group 0.000 claims abstract description 12
125000000217 alkyl group Chemical group 0.000 claims abstract description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
239000011859 microparticle Substances 0.000 claims description 59
229920002472 Starch Polymers 0.000 claims description 56
239000008107 starch Substances 0.000 claims description 56
235000019698 starch Nutrition 0.000 claims description 56
239000000725 suspension Substances 0.000 claims description 27
238000007254 oxidation reaction Methods 0.000 claims description 19
239000001913 cellulose Substances 0.000 claims description 17
229920002678 cellulose Polymers 0.000 claims description 17
230000003647 oxidation Effects 0.000 claims description 16
229910052717 sulfur Inorganic materials 0.000 claims description 16
230000008569 process Effects 0.000 claims description 13
239000001814 pectin Substances 0.000 claims description 10
229920001277 pectin Polymers 0.000 claims description 10
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
239000004005 microsphere Substances 0.000 claims description 8
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 8
WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims description 7
239000004215 Carbon black (E152) Substances 0.000 claims description 6
229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 6
229930195733 hydrocarbon Natural products 0.000 claims description 6
235000011150 stannous chloride Nutrition 0.000 claims description 6
125000004434 sulfur atom Chemical group 0.000 claims description 6
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims description 5
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims description 5
229910052802 copper Inorganic materials 0.000 claims description 5
239000010949 copper Substances 0.000 claims description 5
229910052702 rhenium Inorganic materials 0.000 claims description 5
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 5
239000001119 stannous chloride Substances 0.000 claims description 5
229910052691 Erbium Inorganic materials 0.000 claims description 4
229910052772 Samarium Inorganic materials 0.000 claims description 4
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 4
229910052733 gallium Inorganic materials 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 4
239000012279 sodium borohydride Substances 0.000 claims description 4
229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
229910052727 yttrium Inorganic materials 0.000 claims description 4
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 4
WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims description 3
238000009007 Diagnostic Kit Methods 0.000 claims description 3
150000001720 carbohydrates Chemical group 0.000 claims description 3
150000002739 metals Chemical class 0.000 claims description 3
VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 claims description 2
RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims description 2
UYAHIZSMUZPPFV-NJFSPNSNSA-N erbium-169 Chemical compound [169Er] UYAHIZSMUZPPFV-NJFSPNSNSA-N 0.000 claims description 2
125000000524 functional group Chemical group 0.000 claims description 2
125000005842 heteroatom Chemical group 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims description 2
229920006395 saturated elastomer Chemical group 0.000 claims description 2
229930195734 saturated hydrocarbon Chemical group 0.000 claims description 2
229930195735 unsaturated hydrocarbon Chemical group 0.000 claims description 2
125000001183 hydrocarbyl group Chemical group 0.000 claims 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
UBZPROAIDPYSTK-UHFFFAOYSA-N [Tc++] Chemical compound [Tc++] UBZPROAIDPYSTK-UHFFFAOYSA-N 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 11
238000002360 preparation method Methods 0.000 abstract description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
239000005864 Sulphur Substances 0.000 abstract 1
239000013522 chelant Substances 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
238000006243 chemical reaction Methods 0.000 description 41
239000000047 product Substances 0.000 description 31
239000000243 solution Substances 0.000 description 29
229920000881 Modified starch Polymers 0.000 description 21
239000004368 Modified starch Substances 0.000 description 21
238000002372 labelling Methods 0.000 description 21
230000004048 modification Effects 0.000 description 21
238000012986 modification Methods 0.000 description 21
235000019426 modified starch Nutrition 0.000 description 21
239000002245 particle Substances 0.000 description 21
230000000694 effects Effects 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
239000000203 mixture Substances 0.000 description 13
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
239000008103 glucose Substances 0.000 description 11
239000001254 oxidized starch Substances 0.000 description 11
235000013808 oxidized starch Nutrition 0.000 description 11
150000001299 aldehydes Chemical group 0.000 description 10
238000000921 elemental analysis Methods 0.000 description 10
239000011593 sulfur Substances 0.000 description 10
241001465754 Metazoa Species 0.000 description 8
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 6
102000008100 Human Serum Albumin Human genes 0.000 description 6
108091006905 Human Serum Albumin Proteins 0.000 description 6
239000002262 Schiff base Substances 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
BRWIZMBXBAOCCF-UHFFFAOYSA-N thiosemicarbazide group Chemical group NNC(=S)N BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 6
-1 aldehyde group amine Chemical class 0.000 description 5
230000000052 comparative effect Effects 0.000 description 5
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 5
ILAXBOIRSPXAMM-UHFFFAOYSA-N methyl n-aminocarbamodithioate Chemical compound CSC(=S)NN ILAXBOIRSPXAMM-UHFFFAOYSA-N 0.000 description 5
238000009206 nuclear medicine Methods 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
125000003876 thiosemicarbazone group Chemical group 0.000 description 5
VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
150000002430 hydrocarbons Chemical group 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
229920000945 Amylopectin Polymers 0.000 description 3
150000004753 Schiff bases Chemical class 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
230000005251 gamma ray Effects 0.000 description 3
230000036512 infertility Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
108010013207 macro aggregates of albumin Proteins 0.000 description 3
229960003151 mercaptamine Drugs 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
238000005303 weighing Methods 0.000 description 3
LLCOQBODWBFTDD-UHFFFAOYSA-N 1h-triazol-1-ium-4-thiolate Chemical group SC1=CNN=N1 LLCOQBODWBFTDD-UHFFFAOYSA-N 0.000 description 2
XDSDZQGMWPHUJZ-UHFFFAOYSA-N 2-amino-1h-triazole-5-thione Chemical compound NN1N=CC(=S)N1 XDSDZQGMWPHUJZ-UHFFFAOYSA-N 0.000 description 2
PTVZQOAHCSKAAS-UHFFFAOYSA-N 4-methyl-3-thiosemicarbazide Chemical compound CNC(=S)NN PTVZQOAHCSKAAS-UHFFFAOYSA-N 0.000 description 2
KKIGUVBJOHCXSP-UHFFFAOYSA-N 4-phenylthiosemicarbazide Chemical compound NNC(=S)NC1=CC=CC=C1 KKIGUVBJOHCXSP-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
ZXVCKEPDGHZEMR-UHFFFAOYSA-N CN(C([SH2]C)=S)N Chemical compound CN(C([SH2]C)=S)N ZXVCKEPDGHZEMR-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
238000007259 addition reaction Methods 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229930182478 glucoside Natural products 0.000 description 2
150000008131 glucosides Chemical class 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000003899 penis Anatomy 0.000 description 2
150000003141 primary amines Chemical group 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000003352 sequestering agent Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
CZLPCLANGIXFIE-UHFFFAOYSA-N 1-amino-3-prop-2-enylthiourea Chemical compound NNC(=S)NCC=C CZLPCLANGIXFIE-UHFFFAOYSA-N 0.000 description 1
FCPHVJQWZFNNKD-UHFFFAOYSA-N 3-amino-1,1-dimethylthiourea Chemical compound CN(C)C(=S)NN FCPHVJQWZFNNKD-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101100205030 Caenorhabditis elegans hars-1 gene Proteins 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229940042396 direct acting antivirals thiosemicarbazones Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000002331 radioactive microsphere Substances 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000013112 stability test Methods 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229940056501 technetium 99m Drugs 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
150000003584 thiosemicarbazones Chemical class 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

CZ2002782A 1999-09-01 2000-08-23 Radiofarmaceutické produkty a způsob jejich přípravy CZ2002782A3 (cs)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9910970A FR2797769B1 (fr)	1999-09-01	1999-09-01	Produits radiopharmaceutiques et leur procede de preparation

Publications (1)

Publication Number	Publication Date
CZ2002782A3 true CZ2002782A3 (cs)	2002-08-14

Family

ID=9549465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ2002782A CZ2002782A3 (cs)	1999-09-01	2000-08-23	Radiofarmaceutické produkty a způsob jejich přípravy

Country Status (23)

Country	Link
EP (1)	EP1210127A1 (pl)
JP (1)	JP2003508455A (pl)
KR (1)	KR20020040799A (pl)
CN (1)	CN1371292A (pl)
AU (1)	AU6463100A (pl)
BG (1)	BG106438A (pl)
BR (1)	BR0013729A (pl)
CA (1)	CA2383517A1 (pl)
CZ (1)	CZ2002782A3 (pl)
EA (1)	EA200200307A1 (pl)
EE (1)	EE200200105A (pl)
FR (1)	FR2797769B1 (pl)
HK (1)	HK1044893A1 (pl)
HU (1)	HUP0202714A2 (pl)
IL (1)	IL148076A0 (pl)
MX (1)	MXPA02001923A (pl)
NO (1)	NO20021001L (pl)
NZ (1)	NZ517377A (pl)
PL (1)	PL353803A1 (pl)
SK (1)	SK2772002A3 (pl)
WO (1)	WO2001015746A1 (pl)
YU (1)	YU14202A (pl)
ZA (1)	ZA200201057B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094369B2 (en)	2002-03-29	2006-08-22	Scimed Life Systems, Inc.	Processes for manufacturing polymeric microspheres
US7462366B2 (en)	2002-03-29	2008-12-09	Boston Scientific Scimed, Inc.	Drug delivery particle
US7131997B2 (en)	2002-03-29	2006-11-07	Scimed Life Systems, Inc.	Tissue treatment
US7053134B2 (en)	2002-04-04	2006-05-30	Scimed Life Systems, Inc.	Forming a chemically cross-linked particle of a desired shape and diameter
US7842377B2 (en)	2003-08-08	2010-11-30	Boston Scientific Scimed, Inc.	Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US7449236B2 (en)	2002-08-09	2008-11-11	Boston Scientific Scimed, Inc.	Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US8012454B2 (en)	2002-08-30	2011-09-06	Boston Scientific Scimed, Inc.	Embolization
US7883490B2 (en)	2002-10-23	2011-02-08	Boston Scientific Scimed, Inc.	Mixing and delivery of therapeutic compositions
US7588825B2 (en)	2002-10-23	2009-09-15	Boston Scientific Scimed, Inc.	Embolic compositions
US7976823B2 (en)	2003-08-29	2011-07-12	Boston Scientific Scimed, Inc.	Ferromagnetic particles and methods
US7901770B2 (en)	2003-11-04	2011-03-08	Boston Scientific Scimed, Inc.	Embolic compositions
US7736671B2 (en)	2004-03-02	2010-06-15	Boston Scientific Scimed, Inc.	Embolization
US8173176B2 (en)	2004-03-30	2012-05-08	Boston Scientific Scimed, Inc.	Embolization
US7311861B2 (en)	2004-06-01	2007-12-25	Boston Scientific Scimed, Inc.	Embolization
US9000040B2 (en)	2004-09-28	2015-04-07	Atrium Medical Corporation	Cross-linked fatty acid-based biomaterials
US7858183B2 (en)	2005-03-02	2010-12-28	Boston Scientific Scimed, Inc.	Particles
US7727555B2 (en)	2005-03-02	2010-06-01	Boston Scientific Scimed, Inc.	Particles
US7963287B2 (en)	2005-04-28	2011-06-21	Boston Scientific Scimed, Inc.	Tissue-treatment methods
US9463426B2 (en)	2005-06-24	2016-10-11	Boston Scientific Scimed, Inc.	Methods and systems for coating particles
US7947368B2 (en)	2005-12-21	2011-05-24	Boston Scientific Scimed, Inc.	Block copolymer particles
US7501179B2 (en)	2005-12-21	2009-03-10	Boston Scientific Scimed, Inc.	Block copolymer particles
FR2919189A1 (fr) *	2007-07-26	2009-01-30	Cyclopharma Sa Lab	Nouvelles compositions a base de polyosides greffes par des composes polyamines ou polysoufres.
CN102977174B (zh) *	2012-12-19	2015-04-22	北京师范大学	99mTc(CO)3核标记大环多胺三唑环类葡萄糖基配合物及制备方法和应用
PL240772B1 (pl)	2018-06-11	2022-06-06	Nanothea Spolka Akcyjna	Sposób wytwarzania nanocząstek polimerowych chelatujących izotopy promieniotwórcze do zastosowania w diagnostyce i terapii

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7412164L (sv) *	1974-09-27	1976-03-29	Pharmacia Ab	Medel for intravaskuler administrering
US5672334A (en) *	1991-01-16	1997-09-30	Access Pharmaceuticals, Inc.	Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
WO1994005203A1 (en) *	1992-09-04	1994-03-17	The General Hospital Corporation	Biocompatible polymers containing diagnostic or therapeutic moieties
US5958372A (en) *	1994-06-28	1999-09-28	Nycomed Imaging As	Low viscosity chelating polymers for diagnostic imaging
FR2736834B1 (fr) *	1995-07-17	1997-08-29	Cis Bio Int	Produits radiopharmaceutiques a tropisme cardiaque comportant un complexe nitruro d'un metal de transition et ayant une clairance myocardique rapide

1999
- 1999-09-01 FR FR9910970A patent/FR2797769B1/fr not_active Expired - Fee Related
2000
- 2000-08-23 YU YU14202A patent/YU14202A/sh unknown
- 2000-08-23 CN CN00812300A patent/CN1371292A/zh active Pending
- 2000-08-23 MX MXPA02001923A patent/MXPA02001923A/es not_active Application Discontinuation
- 2000-08-23 SK SK277-2002A patent/SK2772002A3/sk unknown
- 2000-08-23 HU HU0202714A patent/HUP0202714A2/hu unknown
- 2000-08-23 PL PL00353803A patent/PL353803A1/pl unknown
- 2000-08-23 IL IL14807600A patent/IL148076A0/xx unknown
- 2000-08-23 NZ NZ517377A patent/NZ517377A/en unknown
- 2000-08-23 BR BR0013729-4A patent/BR0013729A/pt not_active IP Right Cessation
- 2000-08-23 CA CA002383517A patent/CA2383517A1/en not_active Abandoned
- 2000-08-23 KR KR1020027002820A patent/KR20020040799A/ko not_active Withdrawn
- 2000-08-23 EE EEP200200105A patent/EE200200105A/xx unknown
- 2000-08-23 EP EP00951784A patent/EP1210127A1/en not_active Withdrawn
- 2000-08-23 CZ CZ2002782A patent/CZ2002782A3/cs unknown
- 2000-08-23 EA EA200200307A patent/EA200200307A1/ru unknown
- 2000-08-23 HK HK02106423.2A patent/HK1044893A1/zh unknown
- 2000-08-23 JP JP2001520157A patent/JP2003508455A/ja active Pending
- 2000-08-23 AU AU64631/00A patent/AU6463100A/en not_active Abandoned
- 2000-08-23 WO PCT/IB2000/001161 patent/WO2001015746A1/en not_active Ceased
2002
- 2002-02-06 ZA ZA200201057A patent/ZA200201057B/xx unknown
- 2002-02-26 BG BG06438A patent/BG106438A/bg unknown
- 2002-02-28 NO NO20021001A patent/NO20021001L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
FR2797769A1 (fr)	2001-03-02
FR2797769B1 (fr)	2003-07-25
CN1371292A (zh)	2002-09-25
KR20020040799A (ko)	2002-05-30
EA200200307A1 (ru)	2002-08-29
WO2001015746A1 (en)	2001-03-08
JP2003508455A (ja)	2003-03-04
NO20021001L (no)	2002-04-11
NZ517377A (en)	2003-08-29
AU6463100A (en)	2001-03-26
PL353803A1 (pl)	2003-12-01
EP1210127A1 (en)	2002-06-05
HK1044893A1 (zh)	2002-11-08
CA2383517A1 (en)	2001-03-08
ZA200201057B (en)	2003-07-30
IL148076A0 (en)	2002-09-12
SK2772002A3 (en)	2002-09-10
NO20021001D0 (no)	2002-02-28
HUP0202714A2 (en)	2002-12-28
MXPA02001923A (es)	2003-07-21
YU14202A (sh)	2004-09-03
BR0013729A (pt)	2002-05-07
EE200200105A (et)	2003-04-15
BG106438A (bg)	2002-09-30

Publication	Publication Date	Title
SK2772002A3 (en)	2002-09-10	Radiopharmaceutical products and their preparation procedure
KR101562817B1 (ko)	2015-10-26	방사성약제 조성물을 제조하기 위한 폴리아민이 그라프트된 다당류
JPS641449B2 (pl)	1989-01-11
EP3711781A1 (en)	2020-09-23	Method for preparation of radioisotope chelating polymer nanoparticles for use in diagnostics and treatment
US4250161A (en)	1981-02-10	Method and kit for the preparation of radiopharmaceuticals
EP1268464A1 (en)	2003-01-02	Radioisotope-labeled complexes of glucose derivatives and kits for the preparation thereof
CN117414446A (zh)	2024-01-19	一种荷载核素的可注射温敏凝胶合成方法和用途
JPS63170400A (ja)	1988-07-14	放射性医薬品とその調製用高分子化合物
JPS5842846B2 (ja)	1983-09-22	肝臓および骨髄走査用テクネチウム−９９ｍ標識放射線診断剤とその製造法
LI et al.	0	RADIOPHARMAZEUTISCHE ZUSAMMENSETZUNGEN DIE POLYAMINE GEPFROPFTE POLYSACCHARIDE ENTHALTEN COMPOSITIONS RADIOPHARMACEUTIQUES COMPRENANT DES POLYSACCHARIDES GREFFÉS AVEC DES POLYAMINES
JPH0615478B2 (ja)	1994-03-02	放射性医薬品とその調製用高分子化合物
HK1149211B (en)	2014-01-24	Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions
JPS63170389A (ja)	1988-07-14	放射性医薬品とその調製用高分子化合物
JPH01176000A (ja)	1989-07-12	放射性医薬品とその調製用高分子化合物
CZ277786B6 (en)	1993-04-14	PROCESS FOR PREPARING RADIO DIAGNOSTIC MEANS WITH A COMPLEX 99m Tc-d,1-4,8-DIAZA-3,6,6,9-TETRAMETHYLUNDECANE-2,10-BISOXIME